Drugs / ellagic acid
ellagic acid
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04011618 | Sep 2019 → Dec 2021 | metabolic syndrome X | University of Guadalajara | Unknown | No outcome recorded |
| Phase 2 | NCT00455416 | Apr 2007 → Apr 2009 | follicular lymphoma | Oslo University Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02263378 | Sep 2014 → Mar 2016 | human papilloma virus infection | University of Messina | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ellagic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02263378 ↗ |
| Known as | Acide ellagique | ChEMBL registry synonym — accepted as the source's own label CHEMBL6246 ↗ |
| Known as | Acido elagico | ChEMBL registry synonym — accepted as the source's own label CHEMBL6246 ↗ |
| Known as | NSC-407286 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6246 ↗ |
| Known as | NSC-656272 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6246 ↗ |
| Known as | Pomegranate Extract | “Ellagic Acid / Pomegranate Extract” NCT04011618 ↗ |
| Modality | Small molecule | — CHEMBL6246 ↗ |
| Route | Oral | “Dosage twice a day orally every 12 hours during 12 weeks” NCT04011618 ↗ |